Direct compression of the API powder into veterinary tablets becomes process-valid only after particle size distribution, bulk density, and residual moisture are locked within compendial powder flow specifications. A D50 between 75 µm and 180 µm with a span [(D90−D10)/D50] not exceeding 2.2, an angle of repose below 35°, and a Carr compressibility index below 25% are typical release criteria for rotary press operation at 30–80 rpm without forced feeder intervention. Bulk density below 0.45 g/mL and tapped density above 0.60 g/mL create segregation risk in low-dose formulations below 5 mg active per dose unit because the active powder migrates through excipient voids during hopper discharge and turret vibration. Under those conditions, wet granulation in a high-shear mixer with impeller speed 200–400 rpm and chopper speed 1000–2000 rpm, followed by fluid bed drying at inlet air temperature 60–70°C and product temperature 35–45°C to final moisture 1.5–3.0%, is the standard corrective route. The granulate is then milled through a 0.8–1.25 mm screen, blended with microcrystalline cellulose 20–40 wt%, crospovidone 2–4 wt%, colloidal silicon dioxide 0.5–1.0 wt%, and magnesium stearate 0.5–1.0 wt% for 2–5 min. Compression on a rotary tablet press with precompression force 3–8 kN and main compression force 12–30 kN typically produces tablets with hardness 60–120 N and friability below 1.0% when evaluated per USP ‹1216› or Ph. Eur. 2.9.7. Content uniformity testing per Ph. Eur. 2.9.40 or USP ‹905› requires acceptance value AV ≤15 for individual dosage units below 25 mg active. Dissolution testing per Ph. Eur. 2.9.3 or USP ‹711› is run in 900 mL of pH 1.2, pH 4.5, and pH 6.8 media at 37 ± 0.5°C. Wet granulation should be avoided if the API powder shows more than 2% assay loss after 24 h at 60°C in aqueous slurry, in which case roller compaction at roll pressure 4–8 kN/cm and screen milling to 0.8–1.5 mm granulate is preferred.

Why Does Capsule Filling Impose Tighter Moisture Control Than Tablet Granulation?

Hard capsules present a closed-shell moisture reservoir that tablet cores do not. Gelatin shells equilibrate to moisture content around 13–16% w/w and become brittle below 10% w/w, while hypromellose shells hold 4–8% w/w and tolerate lower RH but may delay disintegration if exposed to high RH. The API powder must therefore be dried to a residual moisture level compatible with the shell, typically below 3.0% for gelatin and below 5.0% for HPMC, unless pre-conditioned at 35–45% RH. Filling on a dosator machine requires the powder plug to retain its shape during transfer; a Carr index below 25% and angle of repose below 38° are necessary to prevent dose weight drift exceeding ±5% at speeds above 60,000 capsules per hour. Tamping pin fillers accept slightly poorer flow but respond to bulk density variation, making tapped density a release surrogate. Lubrication with magnesium stearate 0.5–1.0% should be timed to avoid over-lubrication, which reduces capsule dissolution by increasing hydrophobic surface coverage. In low-dose capsules below 10 mg, the active substance is typically pre-blended with lactose monohydrate or mannitol using geometric dilution in a V-blender at 15–25 rpm for 20–30 min, then passed through a 0.5 mm screen before final blending. Dissolution testing per USP ‹711› using Apparatus II at 50 rpm in 900 mL of 0.1 M HCl or pH 6.8 phosphate buffer is used to control shell crosslinking risk; gelatin shells exposed to trace aldehydes from excipients can form pellicles that slow release. Residual moisture is determined by Karl Fischer titration per USP ‹921› Method Ia, while capsule fill weight variation is assessed by Ph. Eur. 2.9.5. Desiccant sachets containing silica gel or molecular sieve are placed in HDPE containers when the API is hygroscopic; desiccant selection is based on water vapor sorption isotherms at 25°C and 40°C.

Injectable-grade processing of the API powder begins with particle size reduction and pre-dissolution in Water for Injection at 20–25°C under low-shear mixing because high-shear can generate foam and increase surface oxidation. The solution pH is adjusted with 0.1 M hydrochloric acid or sodium hydroxide to a target that balances solubility and stability; if the active substance is a weak base, pH is typically maintained 1–2 units below its pKa to exceed 90% ionisation, while the final injectable solution is buffered with phosphate or citrate buffers not exceeding 50 mM to avoid injection pain and tissue irritation. Tonicity is corrected with sodium chloride or mannitol to 280–320 mOsmol/kg measured by freezing point depression per USP ‹785› or Ph. Eur. 2.2.35. For thermosensitive formulations, the bulk solution is filtered through a 0.45 µm prefilter and then a 0.22 µm PVDF or PES membrane filter; filter integrity is tested by bubble point or diffusion before and after filtration per the filter manufacturer’s specification and ASTM F838-20. Terminal sterilisation by moist heat at 121°C for 15 min with an F0 value not less than 12 min is acceptable only when pre-formulation forced degradation at 121°C shows assay loss below 2% and no unknown impurity above 0.2%. If moisture and thermal stress cause degradation, lyophilisation is used after determining the collapse temperature by freeze-drying microscopy and DSC; a conservative cycle sets shelf temperature −40°C for freezing, primary drying at −25°C to −10°C and 0.1–0.3 mbar, and secondary drying at 25–35°C for 4–8 h. The finished vials are tested for subvisible particles by Ph. Eur. 2.9.19 or USP ‹788› with limits of ≥10 µm ≤6000 particles per container and ≥25 µm ≤600 particles per container, for bacterial endotoxins by USP ‹85› with a limit derived from the maximum veterinary dose, and for sterility by Ph. Eur. 2.6.1 or USP ‹71›. Container closure integrity is evaluated by vacuum decay or methylene blue ingress per USP ‹1207›. Glass vials are depyrogenated at 250°C for 30 min in a dry heat tunnel; stoppers are washed and steam sterilised at 121°C for 30 min. Avoid amine-based buffering agents and formaldehyde-releasing preservatives if the active substance contains aldehyde or amine reactive functional groups. Published data for this specific API powder in veterinary injectable presentations is limited, so the final cycle and filter compatibility must be verified with pilot-scale batches before process validation.

Feed Premix Homogeneity and Cross-Batch Carryover Control in Compound Feed Mills

Medicated premix manufacture requires an active substance carrier system that prevents segregation from bulk feed ingredients. The API powder is diluted to a working premix concentration, often 1–10% w/w active substance, using carriers such as rice hulls, ground corn cob, calcium carbonate, or lactose. A double-shaft paddle mixer or ribbon blender with a working volume of 500–2000 kg is operated at 20–40 rpm for 8–15 min; the mixing endpoint is established by sampling 10 locations with a thief sampler and assaying each sample by HPLC. Homogeneity acceptance is typically a coefficient of variation CV below 5% for a properly milled premix, with individual sample recoveries within 85–115% of the theoretical concentration. Overmixing beyond 25 min can increase electrostatic adhesion to mixer walls or fracture friable carriers, causing assay variability to rise. If the API powder has a D90 greater than 250 µm and the carrier D50 below 100 µm, density segregation produces top-bottom assay gradients; pre-grinding the active substance through a 0.5 mm screen or adding 0.5–1.0 wt% soybean oil reduces dust and free-fall segregation. Carryover of medicated premix into non-medicated feeds is controlled by sequencing batches, flush cleaning with ground corn or wheat middlings, and swab or rinse verification for active residue. In the United States, medicated feed applications fall under FDA 21 CFR 558 relevant requirements, while residual solvents in the API powder are controlled according to VICH GL18. Cross-contamination limits are set from the highest safe concentration in target species and validated by HPLC with a limit of quantitation at or below 1 ppm of active substance in feed. If the compound is light-sensitive, the premix is packed in opaque multi-wall paper bags with a polyethylene liner; if hygroscopic, desiccant clay is added to the carrier at 0.5–1.0 wt%.

Oral solutions and suspensions for veterinary use require solubility mapping before solvent selection. The API powder is dissolved or dispersed at 20–25°C in a co-solvent system selected from propylene glycol, glycerol formal, polyethylene glycol 400, or ethanol, with water as the bulk phase. If the active substance is poorly water-soluble below 1 mg/mL, the formulation may require pH modification with a citrate or phosphate buffer to 50–100 mM and the addition of a wetting agent such as polysorbate 80 at 0.1–0.5% w/v. Multi-dose veterinary oral solutions require antimicrobial preservation; benzyl alcohol at 1.0–1.5% v/v or sodium benzoate at 0.1–0.2% w/v with potassium sorbate is used when the pH is below 5.0. Antioxidants such as sodium metabisulfite 0.05–0.1% w/v are included when forced degradation under 40°C/75% RH shows oxidative impurity increase above 0.2% in 4 weeks. The final solution is filtered through a 5–10 µm polypropylene clarifying filter and filled into amber PET or glass bottles; plastic container suitability is tested per USP ‹661.1› and Ph. Eur. 3.2.2. pH drift in multi-dose containers is a primary stability risk because repeated opening introduces carbon dioxide and shifts carbonate equilibrium; therefore, buffering capacity is verified by titrating a 100 mL aliquot with 0.1 M hydrochloric acid and confirming less than 0.3 unit pH change at 5 mL titrant. Suspension formulations must control sedimentation volume and redispersibility; xanthan gum 0.2–0.5% w/v or microcrystalline cellulose/carboxymethylcellulose sodium 1.0–2.0% w/v is used to achieve a yield stress sufficient to maintain less than 20% sedimentation over 24 h. In-use stability after dilution into drinking water or oral dosing pumps is evaluated at 2 h, 6 h, and 24 h in hard water 250–350 ppm CaCO3 and soft water below 50 ppm CaCO3; published data for this API powder in such matrices is limited and must be generated before line extension.

When Drinking Water Medication Requires Buffered Reconstitution to Prevent Stock Solution Precipitation

Water-soluble powder presentations of the API powder are diluted in drinking water via proportioner pumps set to 0.5–2.0% stock solution, but precipitation at the point of dilution remains the dominant field failure. The API powder is first converted into a wettable, dispersible powder by blending with lactose monohydrate or dextrose and a wetting agent such as sodium lauryl sulfate at 0.5–2.0% w/w. If the active substance has an alkaline pKa, the solution pH may exceed 8.5 in carbonate-rich groundwater, causing deprotonation and precipitate formation; citric acid at 0.5–1.0 g/L or monopotassium phosphate buffer is added to maintain stock solution pH between 6.5 and 7.5. Hardness above 250 ppm CaCO3 can chelate or salt-out the active substance, so EDTA disodium is incorporated at 0.05–0.1% w/w or the drinking water is pre-treated with a water softener. Oxidation by residual chlorine above 2 ppm, especially in municipal water supplies, is mitigated by adding sodium thiosulfate at 0.05–0.1% w/w to the powder. The powder is filled into moisture-barrier foil laminate sachets; residual moisture is controlled below 2.0% by desiccated filling suites and measured by USP ‹921› Karl Fischer titration. Reconstitution testing uses a paddle stirrer at 100 rpm in 1 L glass beakers; wetting time is recorded and the solution is passed through a 0.45 µm membrane filter to detect undissolved particles. Stock solution stability in a closed polyethylene tank is evaluated at 0, 6, 12, and 24 h under 500 lux light; if assay loss exceeds 5% or turbidity exceeds 5 NTU, the in-use shelf life is shortened. Pump calibration with a flow meter is required before each stock solution batch because proportioner diaphragms can drift by ±5% under fluctuating line pressure, altering delivered dose. Final medicated drinking water is sampled from drinker nipples at the furthest line end and assayed by HPLC to confirm delivered concentration within 85–115% of the target.

Dry Granulation as a Pelletising Route When Aqueous Binders Degrade the Active Substance

Granular oral presentations for reconstitution or top dressing use either fluid bed granulation or roller compaction. When the API powder is hydrolytically unstable, dry granulation avoids aqueous binder contact. The compound is blended with microcrystalline cellulose, lactose monohydrate, crospovidone, and a dry binder such as copovidone 3–5% w/w, then compacted on a roller compactor at roll force 4–10 kN/cm, roll speed 8–15 rpm, and screen milled to granules with size 0.5–1.4 mm. The resulting granules are dried to final moisture 1.5–2.5% and packaged in foil-lined sachets. If aqueous granulation is acceptable, fluid bed top spray granulation proceeds with a binder solution of povidone K30 5–10% w/w sprayed at 10–30 g/min per kg of batch, inlet air temperature 60–75°C, product temperature 35–45°C, and atomising air pressure 1.5–2.5 bar; the endpoint is controlled by near-infrared moisture or outlet air temperature. Granule flow and compressibility are evaluated by USP ‹1174› and bulk/tapped density per USP ‹616›. For palatability, the granules are coated with ethylcellulose or polymethacrylate film in a side-vented pan coater at product temperature 30–35°C and spray rate 2–5 g/min/kg; coating thickness is monitored by weight gain 3–8% w/w. Disintegration of the coated granules is tested by Ph. Eur. 2.9.1 with water at 37 ± 0.5°C, and dissolution by Ph. Eur. 2.9.3 with Apparatus II at 75 rpm because paddle speed influences floating granule release. If the granules are for top dressing, sieving through 1.0 mm and dust removal below 0.15 mm are necessary to reduce refusal by food-producing species; published data for the specific API powder on palatability in target species is limited, requiring field acceptance trials.